Из-за периодической блокировки нашего сайта РКН сервисами, просим воспользоваться резервным адресом:
Загрузить через ClipSave.ruУ нас вы можете посмотреть бесплатно Multiple Myeloma: First Line Treatment & Side Effects | Dr. Rafael Fonseca | The Patient Story или скачать в максимальном доступном качестве, которое было загружено на ютуб. Для скачивания выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса savevideohd.ru
This video is part of a series, "Newest Treatment for Multiple Myeloma," made especially for multiple myeloma patients and their caregivers to navigate this fast-changing landscape of options. In this episode, top multiple myeloma specialist, Dr. Rafael Fonseca of Mayo Clinic, lays the groundwork on describing upfront myeloma treatments, from induction therapy, how genetics factor into treatment decisions, to personalizing treatment for each myeloma patient, and side effects. Full transcript: https://www.thepatientstory.com/myelo... FIRST LINE THERAPY (1:09) Dr. Fonseca's background + work focus in myeloma (1:59) What are the best ways to determine treatment? (3:20) First phase of treatment, AKA induction therapy (3:40) Different drugs and administration (5:14) Trying to achieve deepest response possible (5:42) MRD testing (6:49) How genetics factor into treatment decisions (7:30) Logistics of planning treatment with patients (7:48) Personalizing treatment for each patient SIDE EFFECTS (8:38) Doctor's perspective on side effects 1st Line & 2nd Line Side Effects - (9:02) Monoclonal Antibodies side effects - (9:27) Immunomodulatories (IMiDS) Side Effects - (10:27) Proteasome inhibitor side effects - (11:18) Steroid side effects (13:06) What happens if patients can’t handle the side effects of one drug? Thank you to Karyopharm for its support of our educational program. The Patient Story retains full editorial control over all of our content.